CYP2D6 and depressive symptom measurement: AACAP, in its practice parameters, references the agent only briefly, advising clinicians of the significant potential for ‘sedation, weight gain, depression’ as well as recommending ‘CYP2D6 pharmacogenomic testing’, recommendations not shared by the FDA for valbenazine [3].